Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOMP: Selinexor in Combination With Backbone Treatments for Multiple Myeloma
NCT02343042Phase 2Recruiting
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Oct 2015
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of selinexor in multiple myeloma (MM) (12 arms), sponsored by Karyopharm Therapeutics Inc. Primary endpoints: Maximum Tolerated Dose at 12 months, Recommended Phase-2 dose at 12 months and 6 more. Started Oct 2015; status: recruiting.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02343042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02343042.